JP2007211026A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007211026A5 JP2007211026A5 JP2007124042A JP2007124042A JP2007211026A5 JP 2007211026 A5 JP2007211026 A5 JP 2007211026A5 JP 2007124042 A JP2007124042 A JP 2007124042A JP 2007124042 A JP2007124042 A JP 2007124042A JP 2007211026 A5 JP2007211026 A5 JP 2007211026A5
- Authority
- JP
- Japan
- Prior art keywords
- dna plasmid
- papillomavirus
- particles
- capsid protein
- oral administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013612 plasmid Substances 0.000 claims description 26
- 239000002245 particle Substances 0.000 claims description 24
- 241001631646 Papillomaviridae Species 0.000 claims description 22
- 108090000565 Capsid Proteins Proteins 0.000 claims description 20
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 20
- 238000013492 plasmid preparation Methods 0.000 claims description 16
- 239000000872 buffer Substances 0.000 claims description 8
- 239000012139 lysis buffer Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 210000000987 immune system Anatomy 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 241000701822 Bovine papillomavirus Species 0.000 claims description 2
- 241000701806 Human papillomavirus Species 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 210000004877 mucosa Anatomy 0.000 claims description 2
- 244000052769 pathogen Species 0.000 claims description 2
- 230000001717 pathogenic effect Effects 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN01118003A CN1114690C (zh) | 2001-05-15 | 2001-05-15 | 乳头瘤假病毒及其制备方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001321828A Division JP4511090B2 (ja) | 2001-05-15 | 2001-10-19 | Ｄｎａプラスミドワクチン用アジュバンド及びその調製方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007211026A JP2007211026A (ja) | 2007-08-23 |
| JP2007211026A5 true JP2007211026A5 (enExample) | 2008-10-23 |
| JP4472724B2 JP4472724B2 (ja) | 2010-06-02 |
Family
ID=4662911
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001321828A Expired - Fee Related JP4511090B2 (ja) | 2001-05-15 | 2001-10-19 | Ｄｎａプラスミドワクチン用アジュバンド及びその調製方法 |
| JP2007124042A Expired - Fee Related JP4472724B2 (ja) | 2001-05-15 | 2007-05-09 | パピロマウイルス偽ウイルス及びその調製方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001321828A Expired - Fee Related JP4511090B2 (ja) | 2001-05-15 | 2001-10-19 | Ｄｎａプラスミドワクチン用アジュバンド及びその調製方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (3) | US6878541B2 (enExample) |
| JP (2) | JP4511090B2 (enExample) |
| CN (1) | CN1114690C (enExample) |
| WO (1) | WO2002092796A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120164173A1 (en) * | 2001-05-15 | 2012-06-28 | Liang Qiao | Papilloma Pseudovirus and Preparation |
| CN1114690C (zh) | 2001-05-15 | 2003-07-16 | 乔良 | 乳头瘤假病毒及其制备方法 |
| CA2604909A1 (en) | 2005-04-15 | 2006-10-26 | The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services | Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen |
| CA2686990C (en) * | 2007-05-08 | 2018-04-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Papillomavirus pseudoviruses for detection and therapy of tumors |
| CN107252489A (zh) | 2009-04-13 | 2017-10-17 | 法国健康和医学研究院 | Hpv颗粒及其用途 |
| WO2011039646A2 (en) | 2009-09-30 | 2011-04-07 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Papilloma virus -like particles for targeted gene delivery |
| EP2493918A4 (en) | 2009-10-30 | 2013-04-10 | Ntf Therapeutics Inc | IMPROVED NEURTURINE MOLECULES |
| US9700639B2 (en) | 2012-02-07 | 2017-07-11 | Aura Biosciences, Inc. | Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells |
| JP6170077B2 (ja) | 2012-02-16 | 2017-07-26 | エータイアー ファーマ， インコーポレイテッド | 自己免疫および炎症疾患を処置するためのヒスチジルｔＲＮＡ合成酵素 |
| MX385842B (es) | 2013-09-18 | 2025-03-18 | Aura Biosciences Inc | Conjugados de partículas de tipo virus y uso de las mismas. |
| CA3002674A1 (en) | 2015-10-30 | 2017-05-04 | Aleta Biotherapeutics Inc. | Compositions and methods for treatment of cancer |
| AU2016343722A1 (en) | 2015-10-30 | 2018-05-24 | Aleta Biotherapeutics, Inc. | Targeted cancer therapy |
| MX2018005348A (es) | 2015-10-30 | 2018-08-14 | Aleta Biotherapeutics Inc | Composiciones y metodos para transduccion de tumores. |
| US10751398B2 (en) * | 2016-10-07 | 2020-08-25 | Loyola University Chicago | Inflammasome activators and methods of use to treat tumors |
| MX2019015769A (es) * | 2017-06-23 | 2020-08-03 | Verimmune Inc | Partículas tipo virus quiméricas y usos de estas como redireccionadores de respuestas inmunitarias específicos para el antígeno. |
| JP2021502355A (ja) | 2017-11-06 | 2021-01-28 | ザ・ユナイテッド・ステイツ・オブ・アメリカ・アズ・リプリゼンテッド・バイ・ザ・セクレタリー・デパートメント・オブ・ヘルス・アンド・ヒューマン・サービシーズＴｈｅ Ｕｎｉｔｅｄ Ｓｔａｔｅｓ ｏｆ Ａｍｅｒｉｃａ，ａｓ ｒｅｐｒｅｓｅｎｔｅｄ ｂｙ ｔｈｅ Ｓｅｃｒｅｔａｒｙ，Ｄｅｐａｒｔｍｅｎｔ ｏｆ Ｈｅａｌｔｈ ａｎｄ Ｈｕｍａｎ Ｓｅｒｖｉｃｅｓ | 既存の微生物免疫を利用した癌処置 |
| JP2021502822A (ja) | 2017-11-14 | 2021-02-04 | フラウンホファー ゲセルシャフト ツール フェールデルンク ダー アンゲヴァンテン フォルシュンク エー．ファオ． | ｉｎ ｖｉｔｒｏ及びｉｎ ｖｉｖｏでの遺伝子送達のための非ヒトパピローマウイルス |
| JP7641005B2 (ja) | 2018-12-27 | 2025-03-06 | ヴェリミューン インコーポレイテッド | コンジュゲート型ウイルス様粒子および抗腫瘍免疫リダイレクタとしてのその使用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19526752C2 (de) * | 1995-07-21 | 1997-08-07 | Lutz Prof Dr Gissmann | Hocheffiziente Bildung von Papillomavirusähnlichen Partikeln |
| FR2749323B1 (fr) * | 1996-06-04 | 1998-07-10 | Pasteur Merieux Serums Vacc | Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique |
| CA2257822A1 (en) * | 1996-07-17 | 1998-01-22 | The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services | Infectious papillomavirus pseudoviral particles |
| DE69835294T2 (de) * | 1997-09-05 | 2007-07-26 | Medimmune, Inc. | Methode zur in vitro auseinander- und wiederzusammensetzung von papillomavirus virusähnlichen teilchen (vlps) |
| GB9806666D0 (en) * | 1998-03-27 | 1998-05-27 | Stanley Margaret | Antigen preparation and use |
| CN1241636A (zh) * | 1999-07-05 | 2000-01-19 | 第一军医大学珠江医院 | 抗hpv16e6核酶质粒及其在人乳头瘤病毒与肿瘤治疗中的应用 |
| GB0007231D0 (en) * | 2000-03-24 | 2000-05-17 | Chiron Spa | Modified rna for gene delivery |
| CN1114690C (zh) * | 2001-05-15 | 2003-07-16 | 乔良 | 乳头瘤假病毒及其制备方法 |
-
2001
- 2001-05-15 CN CN01118003A patent/CN1114690C/zh not_active Expired - Fee Related
- 2001-10-19 JP JP2001321828A patent/JP4511090B2/ja not_active Expired - Fee Related
-
2002
- 2002-03-22 WO PCT/CN2002/000187 patent/WO2002092796A1/zh not_active Ceased
- 2002-11-14 US US10/294,087 patent/US6878541B2/en not_active Expired - Lifetime
-
2005
- 2005-02-17 US US11/060,034 patent/US7205126B2/en not_active Expired - Fee Related
-
2007
- 2007-04-09 US US11/784,626 patent/US8129144B2/en not_active Expired - Fee Related
- 2007-05-09 JP JP2007124042A patent/JP4472724B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007211026A5 (enExample) | ||
| Shin et al. | COVID-19 vaccine development and a potential nanomaterial path forward | |
| Al-Halifa et al. | Nanoparticle-based vaccines against respiratory viruses | |
| Chavda et al. | mRNA-based vaccine for COVID-19: they are new but not unknown! | |
| JP2009504654A5 (enExample) | ||
| JP2011521654A5 (enExample) | ||
| JP2013537518A5 (enExample) | ||
| RU2017137357A (ru) | Быстрорастворяющаяся лекарственная форма пероральной вакцины, в которой используют крахмал | |
| JP2013533747A5 (enExample) | ||
| CN106659777A8 (zh) | 免疫原性组合产品 | |
| JP2010522698A5 (enExample) | ||
| JP2008530245A5 (enExample) | ||
| JP2009515831A5 (enExample) | ||
| JP2017524682A5 (enExample) | ||
| JP2008505857A5 (enExample) | ||
| Zhang et al. | PH-controlled release of antigens using mesoporous silica nanoparticles delivery system for developing a fish oral vaccine | |
| Rosales-Mendoza et al. | Nanovaccines | |
| JP2013518052A5 (enExample) | ||
| JP2010506926A5 (enExample) | ||
| JP2013505017A5 (enExample) | ||
| JP2008514203A5 (enExample) | ||
| Hashemzadeh et al. | Vaccines based on virus-like nano-particles for use against Middle East Respiratory Syndrome (MERS) coronavirus | |
| JP2006502228A5 (enExample) | ||
| JP2010538619A5 (enExample) | ||
| Wong et al. | COVID-19 Vaccine: Review of the Mechanism of Action of Different Types of Vaccine Li-Ann Wong*, Christina Gertrude Yap, Nowrozy Kamar Jahan, Naganathan Pillai. |